Seroprevalence of Antibodies Specific to RBD of SARS-CoV-2 and Vaccination Coverage Among Adults | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Understanding the presence of adaptive immune responses that are associated with protection from disease (potential protective immunity) caused by SARS-CoV-2 at the population level is critical for public policy. Potential protective immunity can be acquired either through vaccination or past infection.13 We used history of vaccination or presence of antibodies specific to the receptor binding domain (RBD antibodies) of the spike protein of the SARS-CoV-2 virus as potential markers for potential protective immunity as both are strongly associated with presence of neutralizing antibodies.4,5 We conducted surveys and serologic tests in a representative community sample to estimate the fraction of the Los Angeles County (LAC) adult population that had potential protective immunity in April 2021. We tested for differences in potential protective immunity by demographics and whether presence of RBD antibodies waned with time since infection.

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: November 23, 2021.

Published: January 20, 2022. doi:10.1001/jamanetworkopen.2021.44258

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Sood N et al. JAMA Network Open.

Corresponding Author: Neeraj Sood, PhD, Sol Price School of Public Policy, University of Southern California, University Park Campus, 635 Downey Way, Verna and Peter Dauterive Hall, Los Angeles, CA 90089 (nsood@healthpolicy.usc.edu).

Author Contributions: Dr Sood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Sood, Klipp, Kotha, Kovacs, Hu.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Sood, Lam, Kotha, Kovacs, Hu.

Critical revision of the manuscript for important intellectual content: Sood, Pernet, Lam, Klipp, Kovacs, Hu.

Statistical analysis: Sood, Pernet, Lam, Kotha, Hu.

Obtained funding: Sood, Kotha, Hu.

Administrative, technical, or material support: Sood, Pernet, Klipp, Kotha, Hu.

Supervision: Sood, Klipp, Hu.

Conflict of Interest Disclosures: Dr Pernet reported being CEO of EnViro International Laboratories, a nonprofit organization working on emerging diseases and outbreak preparedness. No other disclosures were reported.

Funding/Support: We acknowledge funding from the Conrad N. Hilton Foundation, Office of the President University of Southern California, Los Angeles County Department of Public Health, the U.S. Centers for Disease Control and Prevention, the Keck School of Medicine at USC, and the Keck Family Foundation.

Role of the Funder/Sponsor: Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We are grateful to Paul Simon and William Nicholas from Los Angeles County Department of Public Health for help with research design; Jennifer Holland, Julie McClammy, Elinor Gaida, and Jacqueline Rosales from LRW, a Material Company, for help with data collection; Anna Rodriguez-Vasquez from University of Southern California, for supervising testing sites; Kevin Ramos from University of Southern California, for help with data analysis. George Celis, Siddharth Saharan, Patricia Anthony from University of Southern California for help with antibody testing. They were not compensated for these contributions.

Additional Information: LA County adult population estimates from IPUMS USA are available at https://usa.ipums.org/usa/. LA County confirmed cases of COVID-19 as of April 25, 2021, from Los Angeles County Department of Public Health are available at http://dashboard.publichealth.lacounty.gov/covid19_surveillance_dashboard/. LA County number of adults vaccinated as of April 25, 2021, from Los Angeles County Department of Public Health are available at http://publichealth.lacounty.gov/media/coronavirus/vaccine/vaccine-dashboard.htm.

References
1.
Harvey  RA , Rassen  JA , Kabelac  CA ,  et al.  Association of SARS-CoV-2 seropositive antibody test with risk of future infection.   JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366PubMedGoogle ScholarCrossref
2.
Dan  JM , Mateus  J , Kato  Y ,  et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.   Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063PubMedGoogle Scholar
3.
Dagan  N , Barda  N , Kepten  E ,  et al.  BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.   N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765PubMedGoogle ScholarCrossref
4.
Premkumar  L , Segovia-Chumbez  B , Jadi  R ,  et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.   Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413PubMedGoogle Scholar
5.
Mariën  J , Ceulemans  A , Michiels  J ,  et al.  Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.   J Virol Methods. 2021;288:114025. doi:10.1016/j.jviromet.2020.114025PubMedGoogle Scholar
6.
Sood  N , Simon  P , Ebner  P ,  et al.  Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020.   JAMA. 2020;323(23):2425-2427. doi:10.1001/jama.2020.8279PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close